Preclinical characterization of a novel PI3Kα H1047R mutant-selective inhibitorEUROPEAN JOURNAL OF CANCERIF7.12024-10-010PRE
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profilingINTERNATIONAL JOURNAL OF CANCERIF4.72024-07-120PRE
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint InhibitorsJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORKIF16.42021-12-315OA
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and AzacitidinePHARMACEUTICALSIF4.82021-07-303OAAI
Loss of intra-tumoral RIG-I immune signaling is a potential microbiome-mediated mechanism underlying poor anti-tumor immunity and immunotherapy resistance in mucosal melanomaCANCER RESEARCHIF16.62021-03-012PRE
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversityNATURE COMMUNICATIONSIF15.72020-10-16118OAAI
The therapeutic potential of 5-Azacitidine plus various BH3 mimetics in melanomaCANCER RESEARCHIF16.62020-08-150PRE
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cellsCELL DEATH & DISEASEIF9.62020-06-0852OAAI
BRAF fusions identified in melanomas have variable treatment responses and phenotypesONCOGENEIF7.32018-09-2530PREAI